Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS).

Trial Profile

Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ODIS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jul 2010 Status changed from recruiting to completed, results have been reported.
    • 23 Jul 2010 Results have been reported at the 18th International AIDS Conference (23 Jul)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top